Xenon - NeuroproteXenon

Drug Profile

Xenon - NeuroproteXenon

Alternative Names: XENEX

Latest Information Update: 06 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NeuroproteXeon
  • Class Elements; General anaesthetics
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic brain damage
  • New Molecular Entity No

Highest Development Phases

  • Phase II Chronic brain damage

Most Recent Events

  • 02 Oct 2017 Mallinckrodt and NeuroproteXeon agree to co-promote and co-develop Xenon for Neuroprotection in Australia, Canada, Japan and USA
  • 02 Oct 2017 Updated efficacy data from a phase II trial in Brain damage (Combination therapy) released by NeuroproteXeon
  • 02 Oct 2017 NeuroproteXeon plans the phase III XePOHCAS trial for Neuroprotection (Combination therapy) in early 2018 (NCT03176186)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top